Here are four things to know.
1. Demand for these types of therapies, which use engineered viruses to introduce healthy genetic material into sick patients’ cells, has skyrocketed.
2. GE aims to provide a “factory-in-a-box” service with its Kubio manufacturing units to help drugmakers increase production capacity for the viral-vector-based medicines, according to Reuters.
3. The company already produces off-the-shelf modular factories for other complex biologics like monoclonal antibodies. However, the Kubio factories for viral-vector medicines are much cheaper and faster to build.
4. A GE spokesperson told Reuters the company is already in talks with several potential customers for the new Kubio factories.
More articles on supply chain:
Amazon warehouse workers urinate in bottles to avoid discipline for ‘idle time,’ undercover author finds
‘We can’t view ourselves as the box pushers of a hospital’: 3 experts discuss the evolving hospital supply chain
CVS Health elevates Kevin Hourican to president of CVS Pharmacy: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.